cat no | io1015
ioGlutamatergic Neurons
MAPT P301S/WT™
Human iPSC-derived FTD disease model
A rapidly maturing, consistent and scalable isogenic system to study frontotemporal dementia (FTD).
ioGlutamatergic Neurons MAPT P301S/WT are opti-ox™ precision reprogrammed glutamatergic neurons carrying a genetically engineered heterozygous P301S mutation in the MAPT gene encoding the tau protein.
Place your order
Benchtop benefits
Make True Comparisons
Pair the ioDisease Model Cells with the genetically matched wild-type ioGlutamatergic Neurons to directly investigate the impact of mutant tau protein on disease.
Scalable
Industrial scale quantities are available with industry-leading seeding densities, and at a price point that allows the cells to be used from research to high throughput screening.
Quick
The disease model cells and isogenic control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.
Highly characterised and defined
ioGlutamatergic Neurons MAPT P301S/WT express neuron-specific markers comparably to the isogenic control
.png?width=1715&height=1221&name=ioGlutamatergic_neurons-MAPT-P301S-WT-ICC%20(1).png)
Immunofluorescent staining on post-revival day 11 demonstrates similar homogenous expression of pan-neuronal proteins MAP2 and TUBB3 (upper panel) and glutamatergic neuron-specific transporter VGLUT2 (lower panel) in ioGlutamatergic Neurons MAPT P301S/WT compared to the isogenic control. 100X magnification.
ioGlutamatergic Neurons MAPT P301S/WT form structural neuronal networks by day 11
ioGlutamatergic Neurons MAPT P301S/WT mature rapidly and form structural neuronal networks over 11 days, when compared to the isogenic control. Day 1 to 11 post thaw; 100X magnification.
ioGlutamatergic Neurons MAPT P301S/WT demonstrate gene expression of neuronal-specific and glutamatergic-specific markers following reprogramming
Gene expression analysis demonstrates that at day 11, ioGlutamatergic Neurons MAPT P301S/WT (MAPT P301S/WT) and the isogenic control (WT) lack the expression of pluripotency makers (NANOG and OCT4) whilst robustly expressing pan-neuronal (TUBB3 and SYP) and glutamatergic specific (VGLUT1 and VGLUT2) markers, as well as the glutamate receptor GRIA4. Gene expression levels were assessed by RT-qPCR. Data is shown relative to the parental hiPSC control (iPSC Control), normalised to HMBS. Data represents day 11 post-revival samples; n=2 biological replicates.
Disease-related MAPT is expressed in ioGlutamatergic Neurons MAPT P301S/WT following reprogramming
RT-qPCR analysis demonstrates similar expression level of the MAPT gene in both wild type ioGlutamatergic Neurons (WT) and ioGlutamatergic Neurons MAPT P301S/WT (MAPT P301S/WT) at day 11 post-revival (n=2 replicates). cDNA samples of the parental iPSC line (iPSC Control) were included as a reference.
Disease-related phenotype
Differences in hyperphosphorylation of tau observed in a panel of disease model cells compared to the isogenic control
ioGlutamatergic Neurons disease model cells carrying MAPT P301S/P301S, MAPT N279K/WT and MAPT N279K/N279K mutations show hyperphosphorylation when compared to the isogenic control ioGlutamatergic Neurons (WT) at day 21. The disease model cells carrying MAPT P301S/WT mutation do not show hyperphosphorylation. The bar graphs show total Tau, pTau217/total Tau, pTau202/5/total Tau or pTau404/total Tau in cell bodies, analysed by immunocytochemistry. Statistical analyses performed on 5 cellular replicates in the same plate. Bars showing mean, error bars showing standard deviation. Statistics calculated by one way ANOVA and Tukey posthoc analysis. Data courtesy of Charles River Laboratories.
Cells arrive ready to plate
ioGlutamatergic Neurons MAPT P301S/WT are delivered in a cryopreserved format and are programmed to mature rapidly upon revival in the recommended media. The protocol for the generation of these cells is a two-phase process: Phase 1, Stabilisation for 4 days; Phase 2, Maintenance, during which the neurons mature. Phases 1 and 2 after revival of cells are carried out by the customer.
Industry leading seeding density
Do more with every vial
ioGlutamatergic Neurons MAPT P301S/WT cells are compatible with plates ranging from 6 to 384 wells.
The recommended seeding density is 30,000 cells/cm2, compared to up to 500,000 cells/cm2 for other similar products on the market.
This means scientists are able to do more with every vial and expand experimental design within budget without losing out on quality, resulting in more experimental conditions, more repeats, and more confidence in the data.
One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plates. One Large vial can plate a minimum of 3.6 x 24-well plates, 5.4 x 96-well plates, or 7.75 x 384-well plates.
Running Large-Scale CRISPR Screens in Human Neurons
Watch now
Hoescht(blue)TUBB3(blue)_day4.jpg?width=604&name=bit.bio_ioGlutamatergic%20Neurons_60xMAP2(red)Hoescht(blue)TUBB3(blue)_day4.jpg)
Addressing the Reproducibility Crisis | Driving Genome-Wide Consistency in Cellular Reprogramming
Watch now
Industrialising Cellular Reprogramming: Leveraging opti-ox™ Technology to Manufacture Human Cells with Unprecedented Consistency
Watch now
Modelling neurodegeneration: Human isogenic system to study FTD & ALS
Download
Hoescht(blue)_day12v2.png?width=604&name=bit.bio_ioGlutamatergic%20Neurons_20xMAP2(red)Hoescht(blue)_day12v2.png)
Rethinking Developmental Biology With Cellular Reprogramming
Watch now
.png?width=604&name=Tech%20Nets%20online%20symposium%20header%20(1).png)
Precision Cellular Reprogramming for Scalable and Consistent Human Neurodegenerative Disease Models
Watch now
Development and characterisation of a robust in vitro disease model to study tauopathies
Download
Addressing current challenges of in vitro cell models
Read this blog to find out how experts from across academia and industry are approaching the challenges of reproducibility of in vitro cell models as well as potential solutions.
ioDisease Model
ioGlutamatergic Neurons MAPT P301S/P301S™
cat no. io1018
Order now
ioDisease Model
ioGlutamatergic Neurons MAPT N279K/WT™
cat no. io1009
Order now
ioDisease Model
ioGlutamatergic Neurons MAPT N279K/N279K™
cat no. io1014
Order now
ioWild Type
ioGlutamatergic Neurons™
cat no. io1001
Order now
ioCRISPR-Ready
CRISPR-Ready ioGlutamatergic Neurons™
cat no. ioEA1090
Order now
ioDisease Model
ioGlutamatergic Neurons HTT 50CAG/WT™
cat no. ioEA1004
Order now
ioDisease Model
ioGlutamatergic Neurons TDP‑43 M337V/WT™
cat no. ioEA1006
Order now
ioDisease Model
ioGlutamatergic Neurons PRKN R275W/WT™
cat no. io1013
Order now
ioDisease Model
ioGlutamatergic Neurons GBA null/WT™
cat no. io1007
Order now
ioDisease Model
ioGlutamatergic Neurons TDP‑43 M337V/M337V™
cat no. ioEA1005
Order now
ioDisease Model
ioGlutamatergic Neurons PRKN R275W/R275W™
cat no. io1020
Order now
Wild Type and Isogenic Disease Model cells: A true comparison.
Further your disease research by pairing our wild type cells with isogenic disease models.
